8-K: Cadrenal Stockholders Elect Director, Ratify Auditor

Cadrenal Therapeutics stockholders elected Steven Zelenkofske as a Class III director and ratified WithumSmith+Brown, P.C. as their independent auditor at the 2025 annual meeting.

Summary

• Cadrenal Therapeutics, Inc. held its 2025 annual meeting of stockholders on September 24, 2025.
• As of the record date, July 28, 2025, there were 2,046,854 shares of Common Stock outstanding and entitled to vote.
• A quorum was present with 1,284,746 shares of Common Stock represented in person or by proxy.
• Stockholders elected Steven Zelenkofske as a Class III director to serve until the 2028 annual meeting, with 669,494 votes For, 15,099 Withheld, and 600,153 Broker Non-Votes.
• Stockholders ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 1,207,152 votes For, 64,913 Against, 12,681 Abstentions, and 0 Broker Non-Votes.

Sentiment

Score: 5

Explanation: The filing reports routine corporate governance matters with no unexpected positive or negative outcomes, indicating a neutral sentiment.

Positives

• Both proposals presented at the annual meeting, the election of a director and the ratification of the auditor, were approved by stockholders.
• The appointment of WithumSmith+Brown, P.C. as the independent auditor received strong stockholder support, with 1,207,152 votes in favor.

Future Outlook

Steven Zelenkofske is elected to serve as a Class III director until the Company's 2028 annual meeting of stockholders. WithumSmith+Brown, P.C. is ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Industry Context

The filing details routine corporate governance activities, specifically the outcomes of an annual stockholder meeting, which are standard practices across publicly traded companies to ensure accountability and compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders exercised their voting rights on key corporate governance matters, including director election and auditor ratification.
• The election of a director impacts the composition and oversight capabilities of the board, which is crucial for all stakeholders.

Next Steps

• Steven Zelenkofske will serve as a Class III director until the 2028 annual meeting of stockholders.
• WithumSmith+Brown, P.C. will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

The filing details routine corporate governance matters, specifically the results of the annual stockholder meeting. There are no new financial disclosures, strategic shifts, or material events that would alter an investment thesis. The election of a director and ratification of an auditor are standard procedures and do not provide a basis for a 'buy' or 'sell' recommendation.

Keywords

Cadrenal Therapeutics, CVKD, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K